Schizophrenia – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report. In addition to forecasting lifetime prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in high-income countries.

Clarivate Epidemiology’s schizophrenia forecast will answer the following questions:

• Of all people diagnosed with schizophrenia, how many in each high-income country are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of schizophrenia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following patient populations:

• Diagnosed lifetime prevalent cases of schizophrenia.
• Diagnosed incident cases of schizophrenia.
• Lifetime prevalent cases of schizophrenia.
• Diagnosed lifetime prevalent cases of schizophrenia with cognitive impairment.
• Diagnosed lifetime prevalent cases of schizophrenia with positive symptoms.
• Diagnosed lifetime prevalent cases of schizophrenia with negative symptoms.
• Diagnosed lifetime prevalent cases of schizophrenia with significant positive symptoms.
• Diagnosed lifetime prevalent cases of schizophrenia with significant negative symptoms.
• Diagnosed lifetime prevalent cases of schizophrenia with alcohol abuse.
• Diagnosed lifetime prevalent cases of schizophrenia with dementia.
• Diagnosed lifetime prevalent cases of schizophrenia with depression.
• Diagnosed drug-treated lifetime prevalent cases of schizophrenia.

Note: Coverage may vary by country.